NCT05905770View on ClinicalTrials.gov

Do Alemtuzumab Levels Predict T Cell Chimerism After MSD SCT for SCD?

RecruitingOBSERVATIONAL
Enrollment

20

Participants

Timeline

Start Date

July 15, 2022

Primary Completion Date

November 30, 2024

Study Completion Date

November 30, 2025

Conditions
Sickle Cell Disease
Interventions
DRUG

Alemtuzumab Injection [Campath]

Alemtuzumab 1mg/kg

Trial Locations (1)

1105AZ

RECRUITING

Amsterdam Medical Centre, Amsterdam

All Listed Sponsors
collaborator

Leiden University Medical Center

OTHER

lead

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER